Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that deals/orders/projects/customers/sites/programs are individually bigger, broader, or longer than before for the same offering? We need to look for explicit statements about escalation of unit size. Scan the transcript. Management talks about growth, orders, backlog. They mention order rates up 16% overall, but that's volume. They mention backlog up 22% with 20% organic growth. But do they say the average size of orders has increased? They talk about "bigger orders" or "larger projects"? Let's see. In the Q&A, Mike Hilton says: "I would say what we have seen more recently is some bigger orders coming in and sort of packages with staged deliveries, and some of those things can play out over time, so that's part of what we're seeing as well." That is in response to a question about backlog duration. He says "some bigger orders" but does he compare to the company's own past? He says "more recently" and "some bigger orders" but does he convey a pattern of escalation? He doesn't explicitly say that the average size has stepped up versus what they used to sign. He just says they've seen some bigger orders. Also, he doesn't say that this is a recurring pattern or that it's early. He doesn't say that the results still reflect smaller instances. He just mentions it as a factor. Also, there is mention of "tiered offerings" and "new products" but that's about product lines, not about size of engagements. The question is very specific: does management convey that the unit size of the company's own repeatable business is escalating? I don't see any clear statement like "average order size has increased" or "customers are starting at larger scale" or "follow-on orders are larger." The only possible is that "some bigger orders" but that's vague and not a comparison to past. Also, they talk about "packages with staged deliveries" which might imply larger scope, but again not a clear escalation. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.